TGF-β system: The principal profibrotic mediator of peritoneal adhesion formation

Seminars in Reproductive Medicine

Volumn 26, Issue 4, 2008, Pages 298-312

  Chegini, Nasser ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

Adhesions; Chemokines; Clinical; Cytokines; Growth factors; Molecular; Peritoneum; Proteases; Wound repair

Indexed keywords

CYTOKINE; EOTAXIN; INTERFERON; LEUKOTRIENE; MACROPHAGE INFLAMMATORY PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN; STROMAL CELL DERIVED FACTOR 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR;

ANGIOGENESIS; CELL FUNCTION; ENDOMETRIOSIS; ENZYME INHIBITION; ENZYME SYNTHESIS; FIBROSIS; HIGH RISK PATIENT; HUMAN; IMMUNE RESPONSE; INFLAMMATION; MOLECULAR DYNAMICS; NONHUMAN; PERITONEAL CAVITY; PERITONEUM ADHESION; POSTOPERATIVE COMPLICATION; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW; SCAR FORMATION; SURGICAL RISK; WOUND HEALING;

ADHESIONS; ANIMALS; FEMALE; FIBROSIS; HUMANS; MODELS, BIOLOGICAL; PERITONEAL DISEASES; PERITONEUM; PROTEIN BINDING; TRANSFORMING GROWTH FACTOR BETA; WOUND HEALING;

EID: 50249091719     PISSN: 15268004     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0028-1082388     Document Type: Review

References (127)

1. Diamond MP, Schwartz LB. Prevention of Adhesion Development. In: Sutton C, Diamond MP, eds. Endoscopic Surgery for Gynecologists, 2nd ed. London, United Kingdom: W.B. Saunders; 1994:398-406
2. Lower AM, Hawthorn RJ, Ellis H, O'Brien F, Buchan S, Crowe AM. The impact of adhesions on hospital readmissions over ten years after 8849 open gynaecological operations: an assessment from the Surgical and Clinical Adhesions Research Study. BJOG 2000;107:855-862
3. Lower AM, Hawthorn RJ, Clark D, et al. Surgical and Clinical Research (SCAR) Group Adhesion-related readmissions following gynaecological laparoscopy or laparotomy in Scotland: an epidemiological study of 24 046 patients. Hum Reprod 2004;19:1877-1885
4. Diamond MP, Freeman ML. Clinical implications of postsurgical adhesions. Hum Reprod Update 2001;7:567-576
5. Practice Committee of the American Society for Reproductive Medicine. Control and prevention of peritoneal adhesions in gynecologic surgery. Fertil Steril 2006;86(Suppl 5):S1-S5
6. Zeng Q, Yu Z, You J, Zhang Q. Efficacy and safety of Seprafilm for preventing postoperative abdominal adhesion: systematic review and meta-analysis. World J Surg 2007;31:2125-2131
7. Al-Jaroudi D, Tulandi T. Adhesion prevention in gynecologic surgery. Obstet Gynecol Surv 2004;59:360-370
8. Johns A. Evidence-based prevention of post-operative adhesions. Hum Reprod Update 2001;7:577-579
9. Chegini N. Peritoneal molecular environment, adhesion formation and clinical implication. Front Biosci 2002;7:e91-e115
10. Menke NB, Ward KR, Witten TM, Bonchev DG, Diegelmann RF. Impaired wound healing. Clin Dermatol 2007;25:19-25
11. Rivera AE, Spencer JM. Clinical aspects of full-thickness wound healing. Clin Dermatol 2007;25:39-48
12. Clark RFA. Wound repair. Overview and general consideration. In: Clark RAF, ed. The Molecular Biology of Wound Repair, 2nd ed. New York, NY: Plenum Press; 1996:3-50
13. Holmdahl L, Ivarsson LM. The role of cytokines, coagulation and fibrinolysis in peritoneal tissue repair. Eur J Surg 1999;165:1012-1019
14. Muller SA, Treutner KH, Tietze L, et al. Efficacy of adhesion prevention and impact on wound healing of intraperitoneal phospholipids. J Surg Res 2001;96:68-74
15. Furie B, Furie BC. Thrombus formation in vivo. J Clin Invest 2005;115:3355-3362
16. Gaffney PJ. Fibrin degradation products. A review of structures found in vitro and in vivo. Ann N Y Acad Sci 2001;936:594-610
17. Lijnen HR. Elements of the fibrinolytic system. Ann N Y Acad Sci 2001; 936:226-236
18. Herrick S, Blanc-Brude O, Gray A, Laurent G. Fibrinogen. Int J Biochem Cell Biol 1999;31:741-746
19. Bennett JS. Platelet-fibrinogen interactions. Ann N Y Acad Sci 2001;936:340-354
20. Clemetson KJ, Clemetson JM. Platelet collagen receptors. Thromb Haemost 2001;86:189-197
21. Holly SP, Larson MK, Parise LV. Multiple roles of integrins in cell motility. Exp Cell Res 2000;261:69-74
22. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med 2000;342:1350-1358
23. Heldin CH. Development and possible clinical use of antagonists for PDGF and TGF-b. Ups J Med Sci 2004;109:165-178
24. Wynn TA. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest 2007;117:524-529
25. Li J, Chen J, Kirsner R. Pathophysiology of acute wound healing. Clin Dermatol 2007;25:9-18
26. Raja, Sivamani K, Garcia MS, Isseroff RR. Wound reepithelialization: modulating keratinocyte migration in wound healing. Front Biosci 2007;12:2849-2868
27. Fitzpatrick FA, Soberman R. Regulated formation of eicosanoids. J Clin Invest 2001;107:1347-1351
28. Massague J, Gomis RR. The logic of TGF-beta signaling. FEBS Lett 2006;580:2811-2820
29. Feng XH, Derynck R. Specificity and versatility in TGF-b signaling through Smads. Annu Rev Cell Dev Biol 2005;21:659-693
30. ten Dijke P, Arthur HM. Extracellular control of TGF-b signalling in vascular development and disease. Nat Rev Mol Cell Biol 2007;8:857-869
31. Rifkin DB. Latent transforming growth factor-b (TGF-b) binding proteins: orchestrators of TGF-b availability. J Biol Chem 2005;280:7409-7412
32. Todorovic V, Jurukovski V, Chen Y, Fontana L, Dabovic B, Rifkin DB. Latent TGF-beta binding proteins. Int J Biochem Cell Biol 2005;37:38-41
33. Sterner-Kock A, Thorey IS, Koli K, et al. Disruption of the gene encoding the latent transforming growth factor-beta binding protein 4 (LTBP-4) causes abnormal lung development, cardiomyopathy, and colorectal cancer. Genes Dev 2002;16:2264-2273
34. Chaudhry SS, Cain SA, Morgan A, Dallas SL, Shuttleworth CA, Kielty CM. Fibrillin-1 regulates the bioavailability of TGF-beta1. J Cell Biol 2007;176:355-367
35. Sheppard D. Integrin-mediated activation of latent transforming growth factor. Cancer Metastasis Rev 2005;24:395-402
36. Yang Z, Mu Z, Dabovic B, et al. Absence of integrin-mediated TGFbeta1 activation in vivo recapitulates the phenotype of TGFbeta1-null mice. J Cell Biol 2007;176:787-793
37. Sheppard D. Integrin-mediated activation of transforming growth factor-beta(1) in pulmonary fibrosis. Chest 2001;120:49S-53S
38. Sime PJ, O'Reilly KM. Fibrosis of the lung and other tissues: new concepts in pathogenesis and treatment. Clin Immunol 2001;99:308-319
39. Murphy-Ullrich JE, Poczatek M. Activation of latent TGF-b by thrombospondin-1: mechanisms and physiology. Cytokine Growth Factor Rev 2000;11:59-69
40. Hyytiäinen M, Penttinen C, Keski-Oja J. Latent TGF-beta binding proteins: extracellular matrix association and roles in TGF-beta activation. Crit Rev Clin Lab Sci 2004;41:233-264
41. Barbara NP, Wrana JL, Letarte M. Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-b superfamily. J Biol Chem 1999; 274:584-594
42. Yu L, Border WA, Huang Y, Noble NA. TGF-beta isoforms in renal fibrogenesis. Kidney Int 2003;64:844-856
43. Branton MH, Kopp JB. TGF-b and fibrosis. Microbes Infect 1999;1:1349-1365
44. Koch RM, Roche NS, Parks WT, Ashcroft GS, Letterio JJ, Roberts AB. Incisional wound healing in transforming growth factor-b1 null mice. Wound Repair Regen 2000;8:179-191
45. Crowe MJ, Doetschman T, Greenhalgh DG. Delayed wound healing in immunodeficient TGF-b1 knockout mice. J Invest Dermatol 2000;115:3-11
46. Tyrone JW, Marcus JR, Bonomo SR, Mogford JE, Xia Y, Mustoe TA. Transforming growth factor b3 promotes fascial wound healing in a new animal model. Arch Surg 2000;135:1154-1159
47. Ask K, Bonniaud P, Maass K, Eickelberg O, Margetts PJ, Warburton D, Groffen J, Gauldie J, Kolb M. Progressive pulmonary fibrosis is mediated by TGF-beta isoform 1 but not TGF-beta3. Int J Biochem Cell Biol 2008;40:484-495
48. Freeman ML, Saed GM, Elhammady EF, Diamond MP. Expression of transforming growth factor beta isoform mRNA in injured peritoneum that healed with adhesions and without adhesions and in uninjured peritoneum. Fertil Steril 2003;80:708-713
49. Chegini N, Kotseos K, Zhao Y, et al. Differential expression of TGF-β1 and TGF-β3 in serosal tissues of human intraperitoneal organs and peritoneal adhesions. Hum Reprod 2001;6:1291-1300
50. Hobson KG, DeWing M, Ho HS, Wolfe BM, Cho K, Greenhalgh DG. Expression of transforming growth factor beta1 in patients with and without previous abdominal surgery. Arch Surg 2003;138:1249-1252
51. Chegini N, Rong H, Bennett B, Stone IK. Peritoneal fluid cytokine and eicosanoid levels and their relation to the incidence of peritoneal adhesion. J Soc Gynecol Investig 1999;6:153-157
52. Holmdahl L, Kotseos K, Bergström M, Falk P, Ivarsson ML, Chegini N. Overproduction of transforming growth factor-beta1 (TGF-b1) is associated with adhesion formation and peritoneal fibrinolytic impairment. Surgery 2001;129:626-632
53. Krause TJ, Katz D, Wheeler CJ, Ebner S, McKinnon RD. Increased levels of surgical adhesions in TGFb1 heterozygous mice. J Invest Surg 1999;12:31-38
54. Bonniaud P, Margetts PJ, Ask K, Flanders K, Gauldie J, Kolb M. TGF-beta and Smad3 signaling link inflammation to chronic fibrogenesis. J Immunol 2005;175:5390-5395
55. Flanders KC. Smad3 as a mediator of the fibrotic response. Int J Exp Pathol 2004;85:47-64
56. Dooley S, Hamzavi J, Breitkopf K, et al. Smad7 prevents activation of hepatic stellate cells and liver fibrosis in rats. Gastroenterology 2003;125:178-191
57. Hou CC, Wang W, Huang XR, et al. Ultrasound-microbubble-mediated gene transfer of inducible Smad7 blocks transforming growth factor-beta signaling and fibrosis in rat remnant kidney. Am J Pathol 2005;166: 761-771
58. Kopp J, Preis E, Said H, et al. Abrogation of transforming growth factor-beta signaling by SMAD7 inhibits collagen gel contraction of human dermal fibroblasts. J Biol Chem 2005;280:21570-21576
59. Guo H, Leung JC, Lam MF, et al. Smad7 transgene attenuates peritoneal fibrosis in uremic rats treated with peritoneal dialysis. J Am Soc Nephrol 2007;18:2689-2703
60. Wahab NA, Schaefer L, Weston BS, et al. Glomerular expression of thrombospondin-1, transforming growth factor beta and connective tissue growth factor at different stages of diabetic nephropathy and their interdependent roles in mesangial response to diabetic stimuli. Diabetologia 2005;48:2650-2660
61. Daniel C, Takabatake Y, Mizui M, et al. Antisense oligonucleotides against thrombospondin-1 inhibit activation of TGF-beta in fibrotic renal disease in the rat in vivo. Am J Pathol 2003;163:1185-1192
62. Streit M, Velasco P, Riccardi L, et al. Thrombospondin-1 suppresses wound healing and granulation tissue formation in the skin of transgenic mice. EMBO J 2000;19:3272-3282
63. Kondou H, Mushiake S, Etani Y, Miyoshi Y, Michigami T, Ozono K. A blocking peptide for transforming growth factor-beta1 activation prevents hepatic fibrosis in vivo. J Hepatol 2003;39:742-748
64. Akhurst RJ. Large- and small-molecule inhibitors of transforming growth factor-beta signaling. Curr Opin Investig Drugs 2006;7:513-521
65. Suzuki E, Kim S, Cheung HK, et al. A novel small-molecule inhibitor of transforming growth factor beta type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection. Cancer Res 2007;67:2351-2359
66. Moon JA, Kim HT, Cho IS, Sheen YY, Kim DK. IN-1130, a novel transforming growth factor-beta type I receptor kinase (ALK5) inhibitor, suppresses renal fibrosis in obstructive nephropathy. Kidney Int 2006;70:1234-1243
67. Tojo M, Hamashima Y, Hanyu A, et al. The ALK-5 inhibitor A-83-01 inhibits Smad signaling and epithelial-to-mesenchymal transition by transforming growth factor-beta. Cancer Sci 2005;96:791-800
68. DaCosta Byfield S, Major C, Laping NJ, Roberts AB. SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5, and ALK7. Mol Pharmacol 2004;65:744-752
69. Kapoun AM, Gaspar NJ, Wang Y, et al. Transforming growth factor-beta receptor type 1 (TGFbetaRI) kinase activity but not p38 activation is required for TGFbetaRI-induced myofibroblasts differentiation and profibrotic gene expression. Mol Pharmacol 2006;70:518-531
70. Weng HL, Ciuclan L, Liu Y, et al. Profibrogenic transforming growth factor-beta/activin receptor-like kinase 5 signaling via connective tissue growth factor expression in hepatocytes. Hepatology 2007;46:1257-1270
71. Hui AY, Dannenberg AJ, Sung JJ, et al. Prostaglandin E2 inhibits transforming growth factor beta 1-mediated induction of collagen alpha 1(I) in hepatic stellate cells. J Hepatol 2004;41:251-258
72. Peng H, Cheung AK, Reimer LG, Kamerath CD, Leypoldt JK. Effect of indomethacin on peritoneal protein loss in a rabbit model of peritonitis. Kidney Int 2001;59:44-51
73. Tager AM, Dufour JH, Goodarzi K, Bercury SD, von Andrian UH, Luster AD. BLTR mediates leukotriene B(4)-induced chemotaxis and adhesion and plays a dominant role in eosinophil accumulation in a murine model of peritonitis. J Exp Med 2000;192:439-446
74. Haribabu B, Verghese MW, Steeber DA, Sellars DD, Bock CB, Snyderman R. Targeted disruption of the leukotriene B(4) receptor in mice reveals its role in inflammation and platelet-activating factor-induced anaphylaxis. J Exp Med 2000;192:433-438
75. Saed GM, Al-Hendy A, Salama SA, Diamond MP. Adenovirus-mediated expression of cyclooxygenase-2 anti-sense reverse abnormal genetic profile of human adhesion fibroblasts. Fertil Steril 2008;89(5 Suppl):1455-1460
76. Mehrad B, Keane MP, Strieter RM. Chemokines as mediators of angiogenesis. Thromb Haemost 2007;97:755-762
77. Frangogiannis NG. Chemokines in ischemia and reperfusion. Thromb Haemost 2007;97:738-747
78. Braunersreuther V, Mach F, Steffens S. The specific role of chemokines in atherosclerosis. Thromb Haemost 2007;97:714-721
79. Ludwig A, Weber C. Transmembrane chemokines: versatile 'special agents' in vascular inflammation. Thromb Haemost 2007;97:694-703
80. Gerard C, Rollins BJ. Chemokines and disease. Nat Immunol 2001;2:108-115
81. Horuk R. Chemokine receptors. Cytokine Growth Factor Rev 2001;12:313-335
82. Hoshino A, Kawamura YI, Yasuhara M, et al. Inhibition of CCL1-CCR8 interaction prevents aggregation of macrophages and development of peritoneal adhesions. J Immunol 2007;178:5296-5304
83. Berkkanoglu M, Zhang L, Ulukus M, et al. Inhibition of chemokines prevents intraperitoneal adhesions in mice. Hum Reprod 2005;20:3047-3052
84. El-Hakim A, Chiu KY, Sherry B, Bhuiya T, Smith AD, Lee BR. Peritoneal and systemic inflammatory mediators of laparoscopic bowel injury in a rabbit model. J Urol 2004;172:1515-1519
85. Motomura Y, Kanbayashi H, Khan WI, et al. The gene transfer of soluble VEGF type I receptor (Flt-1) attenuates peritoneal fibrosis formation in mice but not soluble TGF-beta type II receptor gene transfer. Am J Physiol Gastrointest Liver Physiol 2005;288:G143-G150
86. Holsti MA, Chitnis T, Panzo RJ, et al. Regulation of postsurgical fibrosis by the programmed death-1 inhibitory pathway. J Immunol 2004;172:5774-5781
87. Gao Y, Luo L, He F. Effect of monocyte chemotactic protein-1 on the intraperitoneal adhesion formation. J Tongji Med Univ 2000;20:340-342
88. Larbi KY, Dangerfield JP, Culley FJ, et al. P-selectin mediates IL-13-induced eosinophil transmigration but not eotaxin generation in vivo: a comparative study with IL-4-elicited responses. J Leukoc Biol 2003;73:65-73
89. Matsukawa A, Hogaboam CM, Lukacs NW, Lincoln PM, Strieter RM, Kunkel SL. Endogenous monocyte chemoattractant protein-1 (MCP-1) protects mice in a model of acute septic peritonitis: cross-talk between MCP-1 and leukotriene B4. J Immunol 1999;163:6148-6154
90. Mrstik M, Kotseos K, Ma C, Chegini N. Increased expression of interferon-inducible protein-10 during surgically induced peritoneal injury. Wound Repair Regen 2003;11:120-126
91. Fine JS, Jackson JV, Rojas-Triana A, Bober LA. Evaluation of chemokine- and phlogistin-mediated leukocyte chemotaxis using an in vivo sponge model. Inflammation 2000;24:331-346
92. Call DR, Nemzek JA, Ebong SJ, et al. Differential local and systemic regulation of the murine chemokines KC and MIP2. Shock 2001;15:278-284
93. Kopydlowski KM, Salkowski CA, Cody MJ, et al. Regulation of macrophage chemokine expression by lipopolysaccharide in vitro and in vivo. J Immunol 1999;163:1537-1544
94. Gautam SC, Noth CJ, Janakiraman N, Pindolia KR, Chapman RA. Induction of chemokine mRNA in bone marrow stromal cells: modulation by TGF-b1 and IL-4. Exp Hematol 1995;23:482-491
95. Sakata Y, Chancey AL, Divakaran VG, Sekiguchi K, Sivasubramanian N, Mann DL. Transforming growth factor-beta receptor antagonism attenuates myocardial fibrosis in mice with cardiac-restricted overexpression of tumor necrosis factor. Basic Res Cardiol 2008 Jan;103:60-68
96. Nakaya I, Wada T, Furuichi K, et al. Blockade of IP-10/CXCR3 promotes progressive renal fibrosis. Nephron Exp Nephrol 2007;107:e12-e21
97. Kampfer H, Paulukat J, Muhl H, Wetzler C, Pfeilschifter J, Frank S. Lack of interferon-gamma production despite the presence of interleukin-18 during cutaneous wound healing. Mol Med 2000;6:1016-1027
98. Witowski J, Thiel A, Dechend R, et al. Synthesis of C-X-C and C-C chemokines by human peritoneal fibroblasts: induction by macrophage-derived cytokines. Am J Pathol 2001;158:1441-1450
99. Visser CE, Tekstra J, Brouwer-Steenbergen JJ, et al. Chemokines produced by mesothelial cells: huGRO-α, IP-10, MCP-1 and RANTES. Clin Exp Immunol 1998;112:270-275
100. McColl SR, Clark-Lewis I. Inhibition of murine neutrophil recruitment in vivo by CXC chemokine receptor antagonists. J Immunol 1999;163:2829-2835
101. Haslinger B, Mandl-Weber S, Sellmayer A, Sitter T. Hyaluronan fragments induce the synthesis of MCP-1 and IL-8 in cultured human peritoneal mesothelial cells. Cell Tissue Res 2001;305:79-86
102. Zeyneloglu HB, Seli E, Senturk LM, Gutierrez LS, Olive DL, Arici A. The effect of monocyte chemotactic protein 1 in intraperitoneal adhesion formation in a mouse model. Am J Obstet Gynecol 1998;179:438-443
103. Rachfal AW, Brigstock DR. Structural and functional properties of CCN proteins. Vitam Horm 2005;70:69-103
104. Ihn H. Pathogenesis of fibrosis: role of TGF-b and CTGF. Curr Opin Rheumatol 2002;14:681-685
105. Leask A, Abraham DJ. The role of connective tissue growth factor, a multifunctional matricellular protein, in fibroblast biology. Biochem Cell Biol 2003;81:355-363
106. Perbal B. CCN proteins: multifunctional signalling regulators. Lancet 2004;363:62-64
107. Kelly M, Kolb M, Bonniaud P, Gauldie J. Re-evaluation of fibrogenic cytokines in lung fibrosis. Curr Pharm Des 2003;9:39-49
108. Gressner OA, Weiskirchen R, Gressner AM. Biomarkers of hepatic fibrosis, fibrogenesis and genetic pre-disposition pending between fiction and reality. J Cell Mol Med 2007;11:1031-1051
109. Gressner OA, Lahme B, Demirci I, Gressner AM, Weiskirchen R. Differential effects of TGF-beta on connective tissue growth factor (CTGF/CCN2) expression in hepatic stellate cells and hepatocytes. J Hepatol 2007;47:699-710
110. Luo X, Ding L, Chegini N. CCNs, fibulin-1C and S100A4 expression in leiomyoma and myometrium: inverse association with TGF-beta and regulation by TGF-beta in leiomyoma and myometrial smooth muscle cells. Mol Hum Reprod 2006;12:245-256
111. Page-McCaw A, Ewald AJ, Werb Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol 2007;8:221-233
112. Hobeika MJ, Thompson RW, Muhs BE, Brooks PC, Gagne PJ. Matrix metalloproteinases in peripheral vascular disease. J Vasc Surg 2007;45:849-857
113. Hemmann S, Graf J, Roderfeld M, Roeb E. Expression of MMPs and TIMPs in liver fibrosis - a systematic review with special emphasis on anti-fibrotic strategies. J Hepatol 2007;46:955-975
114. Vartak DG, Gemeinhart RA. Matrix metalloproteases: underutilized targets for drug delivery. J Drug Target 2007;15:1-20
115. Yan C, Boyd DD. Regulation of matrix metalloproteinase gene expression. J Cell Physiol 2007;211:19-26
116. Medcalf RL. Fibrinolysis, inflammation, and regulation of the plasminogen activating system. J Thromb Haemost 2007;5(Suppl 1):132-142
117. Paraskevas KI, Baker DM, Vrentzos GE, Mikhailidis DP. The role of fibrinogen and fibrinolysis in peripheral arterial disease. Thromb Res 2008;122:1-12
118. Schouten M, Wiersinga WJ, Levi M, van der Poll T. Inflammation, endothelium, and coagulation in sepsis. J Leukoc Biol 2008;83:536-545
119. Balsara RD, Xu Z, Ploplis VA. Targeting plasminogen activator inhibitor-1: role in cell signaling and the biology of domain-specific knock-in mice. Curr Drug Targets 2007;8:982-995
120. Bertolino P, Deckers M, Lebrin F, ten Dijke P. Transforming growth factor-beta signal transduction in angiogenesis and vascular disorders. Chest 2005;128:585S-590S
121. Saed G, Zhang W, Wie KA, Yelian FD, Diamond MP. The effect of TGF-β and hypoxia on fibronectin expression. Reproductive Sciences 2000;7:348-354
122. Ma C, Tarnuzzer RW, Chegini N. Expression of matrix metalloproteinases and tissue inhibitor of matrix metalloproteinases in mesothelial cells and their regulation by transforming growth factor-beta1. Wound Repair Regen 1999;7:477-485
123. Chegini N, Kotseos K, Zhao Y, et al. The expression of matrix metalloproteinase (MMP-1) and tissue inhibitor of MMP (TIMP-1) in serosal tissue of intraperitoneal organs and adhesions. Fertil Steril 2001;76:1212-1219
124. Chegini N, Kotsesos K, Bennett B, et al. Matrix metalloproteinase (MMP-1) and tissue inhibitor of MMP (TIMP-1) in peritoneal fluids and sera, and correlation with peritoneal adhesions. Fertil Steril 2001;76:1207-1211
125. Sharpe-Timms KL, Zimmer RL, Jolliff WJ, Wright JW, Nothnick WB, Curry TE. Gonadotropin-releasing hormone agonist (GnRH-a) therapy alters activity of plasminogen activators, matrix metalloproteinases, and their inhibitors in rat models for adhesion formation and endometriosis: potential GnRH-a-regulated mechanisms reducing adhesion formation. Fertil Steril 1998;69:916-923
126. Agren MS, Werthén M. The extracellular matrix in wound healing: a closer look at therapeutics for chronic wounds. Int J Low Extrem Wounds 2007;6:82-97
127. Diamond MP, El-Hammady E, Wang R, Saed G. Regulation of matrix metalloproteinase-1 and tissue inhibitor of matrix metalloproteinase-1 by dichloroacetic acid in human fibroblasts from normal peritoneum and adhesions. Fertil Steril 2004;81:185-190